Fatigue is associated with excess mortality in the general population: results from the EPIC-Norfolk study

Table 3 The risks of cardiovascular disease related mortality by SF-36 vitality score in the EPIC-Norfolk study

Mortality	SF-36 vitality score quartiles				p-value^a
Mortality	76–100	65–75	50–64	0–49
Model A: unadjusted full dataset HR (95 % CI)	1 (reference)	0.98 (0.84–1.15)	1.25 (1.07–1.46)	1.63 (1.40–1.89)	<0.001
Model B: unadjusted with removal of baseline CVD/cancer HR (95 % CI)	1 (reference)	0.92 (0.77–1.09)	1.18 (1.00–1.40)	1.41 (1.19–1.67)	<0.001
Model C: confounders HR (95 % CI)	1 (reference)	0.93 (0.78–1.12)	1.21 (1.00–1.45)	1.45 (1.18–1.78)	<0.001
Model D: confounders + Hb HR (95 % CI)	1(reference)	0.93 (0.77–1.13)	1.21 (1.00–1.48)	1.43 (1. 15–1.78)	<0.001
Model E: confounders + TSH HR (95 % CI)	1 (reference)	0.85 (0.68–1.05)	1.22 (0.98–1.52)	1.31 (1.03–1.68)	0.001
Model F: confounders + CRP HR (95 % CI)	1 (reference)	0.96 (0.77–1.20)	1.16 (0.92–1.45)	1.38 (1.07–1.79)	0.021
Model G: confounders + Hb, CRP, TSH HR (95 % CI)	1 (reference)	0.84 (0.64–1.09)	1.20 (0.92–1.56)	1.26 (0.93–1.70)	0.025

^aAcross quartiles
Model A: unadjusted; Model B: unadjusted with removal of baseline CVD/cancer; Model C: Model B + statistically proven confounders – age, gender, body mass index, marital status, smoking, education, alcohol, social class, diet, physical activity, beta blocker, depression, pain, diabetes; Model D: Model C plus Hb adjusted; Model E: Model C plus TSH adjusted; Model F: Model C plus CRP adjusted; Model G: Model C plus Hb, CRP and TSH adjusted
CI confidence interval, CRP C-reactive protein, CVD cardiovascular disease, Hb haemoglobin, HR hazard ratio, TSH thyroid-stimulting hormone

ISSN: 1741-7015